Literature DB >> 1556702

Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production.

M Brozik1, I Rosztóczy, K Merétey, G Bálint, M Gaál, Z Balogh, M Bart, M Mituszova, V Velics, A Falus.   

Abstract

Interleukin 6 (IL-6), a multifunctional cytokine particularly active in regulation of the acute phase response, governs the terminal maturation of B lymphocytes and participates in early activation of T cells. IL-6 levels of synovial fluids of 153 patients with different arthritides were measured by a simple sandwich enzyme immunoassay. Highest IL-6 concentrations were detected in patients with rheumatoid arthritis (RA), particularly in those characterized by very active general symptoms and severe joint pain. High IL-6 levels were detected in patients with juvenile RA with polyarticular onset of disease and in gout. Corresponding to the suggested in vivo relevance of IL-6, dose correlation of IL-6 levels with the synovial IgM rheumatoid factor accumulation was demonstrated. The rate of the correlation between synovial IL-6 level and concentration of serum C-reactive protein in RA was inversely proportional to the dose of steroid treatment in patients with RA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1556702

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

1.  Lack of association of interleukin-6 and interleukin-8 gene polymorphisms in Chinese patients with systemic lupus erythematosus.

Authors:  Chung-Ming Huang; An-Ping Huo; Chang-Hai Tsai; Chi-Lan Chen; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

2.  Comparison of microheterogeneity of alpha-1-acid-glycoprotein in serum and synovial fluid from rheumatoid arthritis patients.

Authors:  J K Lacki; K Klama; W Samborski; S H Mackiewicz; W Muller
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

3.  Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice.

Authors:  F A van de Loo; S Kuiper; F H van Enckevort; O J Arntz; W B van den Berg
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

4.  Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts.

Authors:  H Takayanagi; T Juji; T Miyazaki; H Iizuka; T Takahashi; M Isshiki; M Okada; Y Tanaka; Y Koshihara; H Oda; T Kurokawa; K Nakamura; S Tanaka
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 5.  Use of biologics in the treatment of childhood rheumatic diseases.

Authors:  T Arkachaisri; T J Lehman
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

6.  Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis.

Authors:  B A Eberhard; R M Laxer; U Andersson; E D Silverman
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

7.  Inhibiting interleukin-6 in rheumatoid arthritis.

Authors:  Ernest Choy
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

Review 8.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

9.  Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis.

Authors:  F M Cicuttini; K A Byron; D Maher; A M Wootton; K D Muirden; J A Hamilton
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

10.  Circulating interleukin 10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report.

Authors:  J K Lacki; K Klama; S H Mackiewicz; U Mackiewicz; W Müller
Journal:  Inflamm Res       Date:  1995-01       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.